Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 1.8% – What’s Next?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s stock price dropped 1.8% during mid-day trading on Friday . The company traded as low as $1.10 and last traded at $1.11. Approximately 149,388 shares traded hands during trading, an increase of 29% from the average daily volume of 115,581 shares. The stock had previously closed at $1.13.

Actinium Pharmaceuticals Stock Down 1.8%

The company has a market capitalization of $34.63 million, a P/E ratio of -0.80 and a beta of -0.31. The business has a 50 day simple moving average of $1.21 and a 200-day simple moving average of $1.41.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. North Star Asset Management Inc. increased its position in Actinium Pharmaceuticals by 100.0% in the 2nd quarter. North Star Asset Management Inc. now owns 20,000 shares of the company’s stock valued at $28,000 after acquiring an additional 10,000 shares during the period. Mayport LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter valued at $35,000. AM Investment Strategies LLC bought a new stake in shares of Actinium Pharmaceuticals during the fourth quarter valued at about $40,000. Qube Research & Technologies Ltd acquired a new stake in Actinium Pharmaceuticals in the second quarter worth about $70,000. Finally, Bailard Inc. bought a new position in Actinium Pharmaceuticals in the 4th quarter valued at about $79,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.